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Abstract 
Objective 
The immunopathogenesis of SLE is heterogeneous. Responses to rituximab in skin 
are variable.  We performed a detailed assessment of cutaneous responses to 
determine the phenotype of rituximab-responsive disease. 
Methods 
82 SLE patients receiving rituximab were prospectively studied.  32 had significant 
skin involvement before or after treatment. Disease activity was assessed using 
BILAG-2004. Cutaneous lupus subtype was classified by a dermatologist as acute, 
subacute or chronic cutaneous lupus erythematosus (ACLE, SCLE, CCLE) or other 
skin diseases, with supportive photographs or biopsies where necessary. 
Results 
10/26 (39%) patients with baseline skin disease had a beneficial cutaneous 
response to rituximab at 6 months with good response in ACLE (6/14, 43%), and 
poor responses in CCLE (0/8, p=0.034).  Clinical response was associated with 
negative anti-RNP (p=0.024) and anti-Ro (p=0.035) serology. Flares of SCLE and 
CCLE occurred in 12 patients who either had no skin disease or ACLE at baseline 
(i.e. a switch in subtype). Concomitant antimalarials or conventional 
immunosuppressive were not associated with response or flare rate.  Post-treatment 
biopsies confirmed typical active SLE histology in lesions occurring during B cell 
depletion. 
Conclusion 
Clinical response to rituximab in cutaneous manifestations of SLE depends on 
subtype.  No CCLE patient responded and new CCLE lesions were observed during 
B cell depletion, suggesting that initiation and activity of these lesions is not B cell-
dependent.  Flares of a range of skin diseases after B cell depletion may indicate a 
change in immune regulation following B cell-targeted therapy. 
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Disease activity in systemic lupus erythematosus is (SLE) is inadequately controlled 
by conventional therapies(1-3).  Targeted therapies may improve control of 
inflammation and several different molecules are under investigation or in clinical 
use.  SLE is heterogeneous in immunopathogenesis as well as clinical phenotype 
and the range of potential targets under investigation reflect this.  Many new agents 
target B cell function.  Others target Type 1 interferons, T cell co-stimulation, 
cytokines or plasma cells(1). Of these agents, experience is greatest for B cell 
depletion using rituximab.  However, this agent also has the most diverse outcomes 
with positive case series and negative clinical trials. The latter have been attributed 
to defects in trial design and/or outcome measures(2).  Belimumab is licensed and 
proven to be effective.  However, effect size is difficult to judge with a novel 
composite endpoint and small improvement in response rate compared to placebo. It 
is currently not clear whether the low response rates for these agents are due to an 
inappropriate mechanism of action, or pharmacodynamic factor (e.g. patients with 
non-B cell-mediated disease, or failure of drugs to adequately block pathogenic B 
cell function), or due to failure of clinical trial designs and outcome measures to 
accurately represent their efficacy(2). 
Given the heterogeneity of SLE, a single therapeutic target may not be appropriate 
for all patients and disease manifestations. Cutaneous lupus is particularly 
heterogeneous.  Although immune complex deposition is a common feature, non-B 
cell mechanisms are important with keratinocyte activation and apoptosis, 
inflammatory cytokine and chemokine production and a plasmacytoid dendritic cell 
and T cell infiltrate(4).   The common occurrence of some subtypes of cutaneous LE 
in autoantibody-negative patients without SLE in other organs also suggests that the 
contribution of autoimmune B cells may not be essential to all subtypes. 
In our previous study of rituximab in SLE we reported less consistent clinical 
response in the mucocutaneous domain of the BILAG(5).  We therefore undertook 
detailed assessment of cutaneous SLE in a study of 32 patients to identify features 
associated with response and flare after rituximab. 
Patients and Methods 
Patients and therapy 
82 patients receiving rituximab therapy for SLE in a single centre were prospectively 
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studied.  All met ACR/SLICC criteria for SLE.  Treatment protocol and overall clinical 
outcomes of the first 41 patients have been described in previous reports, which 
included 16 of the patients in the present study(5, 6).  Usual criteria for rituximab 
therapy were: active SLE rating 1 x BILAG A or 2 x BILAG B in any domain(s), failure 
of previous immunosuppressive therapy including cyclophosphamide due to 
inefficacy or toxicity, or contraindication to cyclophosphamide.  Patients received 2 x 
1000mg infusions of rituximab on days 1 and 15, each preceded by 100mg 
methylprednisolone.  Concomitant antimalarial or immunosuppressive therapy used 
at baseline was continued.  All patients were followed up for at least 6 months. 
32 patients with significant mucocutaneous manifestations of SLE before or after 
rituximab therapy were analysed.  26 of these patients had active mucocutaneous 
disease at baseline as a primary or co-primary indication for treatment, and were 
analysed for characteristics and predictors of response.  6 of these patients, as well 
as a further 6 patients who had not had skin disease prior to rituximab, had flares of 
new or different skin disease after rituximab. The clinical characteristics of these 12 
patients with flares of cutaneous SLE during B cell depletion were compared to the 
20 patients with cutaneous SLE who did not flare. 
Classification of skin morphology 
Patients were assessed in a combined rheumatology-dermatology clinic.  The 
Gilliam classification terminology was used by a consultant dermatologist to 
categorise cutaneous lupus erythematosus as acute (ACLE), subacute (SCLE), 
chronic cutaneous (CCLE), lupus erythematosus non-specific(LENS, e.g. vasculitis) 
or non-lupus erythematosus skin diseases (NONLE, e.g. psoriasis) for summary 
statistics and evaluation of the association with response and flare(7).  A detailed 
description of each lesion was documented and is given in the supplementary 
information (Table S1). 
Classification of response 
Clinical assessment was performed at baseline and 6 months using BILAG-2004(8).  
Additional flare visits were performed if clinically indicated and documented.  In order 
to differentiate cutaneous response from overall response, BILAG score has been 
expressed as a cutaneous response based on the mucocutaneous domain and other 
dermatological features, and non-cutaneous BILAG response category based on the 
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other 9 domains of BILAG-2004.  Confirmatory photographs or biopsies were 
obtained where necessary.  Consent to publication of photographs was obtained 
using Leeds Teaching Hospitals NHS Trust consent. 
Cutaneous Response 
Cutaneous response and flare were classified according to BILAG mucocutaneous 
domain score, change in morphology and change in therapy.  Mucocutaneous 
response was defined as reduction of BILAG A to B, C or D; reduction of BILAG B to 
C or D; reduction of BILAG C to D (the last definition applied to mild mucosal 
ulceration, mild alopecia or chilblains in this study) with no new topical or 
immunosuppressive therapy for skin disease.  Flare was defined as either (i) new 
BILAG mucocutaneous A-C disease in a patient with no cutaneous involvement at 
the time of RTX, or (ii) a new cutaneous lupus morphology in a patient with or 
without other mucocutaneous LE at baseline. 
 Non Cutaneous Response 
Data were presented for the most frequent non-cutaneous domains 
(musculoskeletal, renal and neurological) for patients with domains rated A or B at 
baseline.  Overall disease activity was presented as number and percentage of 
patients with a BILAG A, B or C score before or 6 months after rituximab.  In order to 
demonstrate association between cutaneous and non-cutaneous response, this was 
converted into a total numerical score for the whole group of patients (A=12, B=8, 
C=1, D/E=0)(9). 
B cell depletion 
B cell subsets were measured using a highly sensitive B cell assay that can 
reproducibly enumerate B cells at 0.0001 x 109 cells/liter, which we previously 
demonstrated to predict clinical response(5).   
Statistical Analysis 
Summary statistics were presented as proportions of patients.  Association between 
clinical and immunological features and response or flare was tested using Chi 
Square tests. 
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Histological Analysis 
Haematoxylin and eosin stained biopsies were scored (by Dr Edward) for presence 
of vacuolar degeneration of keratinocytes, basement membrane thickening, interface 
dermatitis, perivascular and perifollicular infiltration of lymphocytes, neutrophil 
infiltration and follicular plugging.  Staining for dermal mucin and 
immunofluorescence for IgM, IgG and C3c was performed where necessary to 
establish the diagnosis. 
 
Results 
Overall BILAG responses 
Overall, 26 patients had mucocutaneous disease before rituximab and of these, 10 
(38.5%) had mucocutaneous response.  
Scores have been summarised in Figure 1a for the 4 most commonly involved 
BILAG domains.  Musculoskeletal domain score improved by at least 1 grade in 
14/14 patients rated A or B at baseline, and by 2 grades in 5/14.  Renal domain 
score improved by at least 1 grade in 7/7 patients rated A or B at baseline and by 2 
grades in 5/7.  Neurological domain score improved from B to C in 5/6 patients rated 
B at baseline, and remained rated B in 1/6. 
Other than these 4 domains, BILAG A or B disease was also present in 
Haematology (4 cases), General (3 cases) and Cardiorespiratory (3 cases) of which 
all improved by at least 1 grade. 
Mucocutaneous non-response was not associated with lack of response in other 
domains.  There was a substantive reduction in total numerical domain score for the 
musculoskeletal, renal and neurological domains regardless of mucocutaneous 
response (Figure 1b). 
Prediction of mucocutaneous response 
Clinical features 
Clinical and immunological features of patients with or without cutaneous response 
were compared.  Details are shown in Table 1.  Most patients had either ACLE 
(malar rash or more widespread photoaggravated maculopapular rash, usually in the 
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context of active disease in other organs) or CCLE (cutaneous or mucosal discoid 
LE of chilblains).  Response rates in these subtypes were significantly different 
(p=0.034).  Notably, none of the patients with CCLE had mucocutaneous response 
to rituximab.  Details of individual patient responses are shown in Supplement 1 
(Table S1).  LE non-specific lesions were seen in 2 patients with vasculitis and skin 
disease and resolved completely in both.  2 patients had subacute LE, with 
widespread papulosquamous LE, and 1 responded completely. 
Biomarkers 
Unlike disease in other organs, no association between degree of initial B cell 
depletion and clinical response was observed for cutaneous disease.   There were 
trends for association between anti-dsDNA antibodies and mucocutaneous response 
(p=0.075), and anti-Ro and mucocutaneous non-response (p=0.031).  These 
relationships may be explained by these features being associated with ACLE and 
CCLE subtypes respectively (9/14 (64%) of ACLE patients were anti-dsDNA positive, 
6/8 (75%) of CCLE patients were anti-Ro positive).  There was a significant 
association between anti-RNP and mucocutaneous non-response (0/7 RNP positive 
patients responded, p=0.028).  This could not clearly be explained by association 
with other clinical features at baseline (4/14 patients with ACLE (29%) and 2/8 
patients with CCLE (25%) were anti-RNP positive). 
Antimalarial or concomitant immunosuppressant use was not associated with 
cutaneous subtype at baseline and was not associated with better clinical response.  
Indeed, there was a trend to better response in patients not using antimalarials. 
Prediction of mucocutaneous flare 
Flares were observed in 12 patients.  Of these, 9 were clinically typical cutaneous 
lupus lesions (4 annular SCLE, 5 localised or disseminated discoid LE).  3 patients 
had atypical LE lesions or diseases not usually associated with SLE (1 patient with 
biopsy-proven plaque psoriasis; 1 patient with biopsy-proven pemphigus; 1 patient 
with psoriasiform lesions with histological features of lupus). 
Flares occurred in patients with ACLE or no skin disease at baseline.  Hence, of the 
patients with ACLE who initially responded, a proportion developed SCLE or CCLE 
following B cell depletion.  Other than cutaneous lupus morphology there was only a 
weak trend for association between flare and incomplete B cell depletion and a trend 
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to association with negative anti-Sm antibodies.  There was no evidence that 
concomitant antimalarials or conventional immunosuppressives agents prevented 
flares. 
Histological Studies 
Details of histological studies are shown in Supplement 1 (Table S2).  Pre-treatment 
biopsies confirmed that the cases treated had typical lupus appearances 
histologically.  We did not identify specific features predictive of response.  Post-
treatment biopsies confirmed that patients with continuing skin activity or flares of LE 
or other diseases had histological features to support diagnosis.  Variable 
immunofluorescence for IgM, IgG and C3c was observed in patients with active CLE 
before and after rituximab.  
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Discussion 
In this study we explain variability in efficacy of rituximab in SLE by linking clinical 
response to cutaneous morphology and antibody status.  This is the first evidence 
that clinical subgroups of SLE patients may require different targeted therapies. Our 
key findings were that response was better in patients with ACLE (often receiving 
treatment in the context of systemic multi-organ disease) than in SCLE or chronic 
cutaneous forms.  Further underlining the resistance of non-ACLE skin 
manifestations to rituximab we noted that, in several patients, flares of SCLE and 
CCLE were observed after rituximab at a time of near-complete or complete B cell 
depletion.  Despite these negative outcomes in cutaneous disease, these patients 
simultaneously responded well in other organ systems.  We could not explain these 
results in terms of concomitant therapies used or depth of B cell depletion.  Hence 
our results suggest that the role of B cells in CCLE differs from other cutaneous or 
systemic manifestations of SLE.  This conclusion is consistent with the well-known 
occurrence of discoid LE in autoantibody-negative individuals who never develop 
manifestations of SLE in other organs. 
Innate and T cell mechanisms have been described that may predominate in these 
lesions and account for non-response to B cell depletion (reviewed in (10)).  
Cutaneous LE is initiated by keratinocyte apoptosis, commonly in response to UV 
light exposure.  This leads to surface expression of typical lupus antigens, such as 
Ro and other danger signals.  The expression of these antigens may be exacerbated 
by defects of apoptotic clearance in some patients.  Sensing of nuclear antigen by 
plasmacytoid dendritic cells (via Toll-like receptors) leads to the production of Type 1 
interferons, which have numerous effects in triggering local inflammation and 
autoimmunity.  Keratinocytes activated by UV light or danger signals generate 
inflammatory cytokines as well as chemokines that lead to tissue inflammation as 
well as a CD4 and CD8 T cell infiltrate.  
B cells and plasma cells may exacerbate tissue inflammation.  Generation and 
deposition of autoantibody-containing immune complexes may lead to local 
complement activation, as well as increasing IFN production by plasmacytoid 
dendritic cells(11).  However, even if B-plasma cell functions assist in the initiation of 
cutaneous lesions, the above model would suggest they may not always be essential 
to their perpetuation. 
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An additional finding in our study was a relationship between the presence of specific 
autoantibodies and response to rituximab.  Anti-dsDNA and anti-Ro were associated 
with better and worse clinical response respectively.  These antibodies were also 
associated with clinical subtypes of SLE, and it is therefore unclear from our results 
whether a patient with ACLE and anti-dsDNA will respond better than a patient with 
ACLE and Ro.  RNP appeared to be predictive of outcome independent of CLE 
lesional morphology. We note that anti-RNP-containing immune complexes stimulate 
plasmacytoid dendritic cells to produce type I interferons via TLR7 (in contrast to the 
TLR9 mediated effects of anti-dsDNA antibodies), and give rise to a particular 
pattern of Toll-Like Receptor activation(12, 13).  Hence this observation may also be 
consistent with the notion that, once initiated, TLR-IFN innate immune mechanisms 
may lead to disease that is resistant to B cell targeting. 
Whilst B cells may not be required for the persistence of cutaneous lupus, the 
frequency and characteristics of the flares of CLE or even other skin diseases after 
rituximab also require explanation. We postulate two additional processes that might 
account for these cases.  First, B cells may have regulatory effects in some 
circumstances via their secretion of IL-10.  IL-10 counter-regulates IL-12, which in 
turn regulates expression of T cell cutaneous lymphocyte antigen (CLA) and 
therefore T cell homing to the skin (implicated in all the diseases observed here).  
Second, B cell lysis may itself have pro-inflammatory effects – suggested by the 
transient nature of some lesions we observed early after treatment. 
These results indicate the importance of detailed phenotyping of patients in 
assessment of outcomes of targeted therapies in clinical trials.  The BILAG index 
allows differentiation of better responses in different organ systems(8).  The 
Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) allows a 
more detailed assessment of skin involvement, including differentiation of activity 
and scarring(14).  However, neither of these indices capture clinical morphology or 
histological features.  Whilst further validation of our results is required, we suggest 
that this information may be essential for the appropriate treatment and monitoring of 
SLE patients for biologic therapy both in trials and clinical practice.  
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Tables 
Table 1: Factors associated with cutaneous response to rituximab 
Characteristic Total 
(n=26) 
Cutaneous 
Response 
(n=10) 
Cutaneous non-
response or 
worsening 
(n=16) 
p 
Subtype of skin disease 
     ACLE 14 6/14 (42.9%) 8/14 (57.1%) 
0.034 
     SCLE 2 1/2 (100%) 1/2 (0%) 
     CCLE 8 0/8 (0%) 8/8 (100%) 
     LENS 2 
2/2 (100%) 
0/2 (0%) 
Serology 
     dsDNA 14 7/9 (77.8%) 6/17 (35.3%) 0.075 
     Ro 16 3/9 (33.3%) 13/15 (76.5%) 0.031 
     La 8 2/9 (22.2%) 6/17 (35.3%) 0.492 
     Sm 4 1/9 (11.1%) 3/17 (17.6%) 0.660 
     RNP 7 0/9 (0.0%) 7/17 (41.2%) 0.024 
     Low C3 9 3/9 (33.3%) 6/17 (35.3%) 0.920 
     Low C4 11 4/9 (44.4%) 7/17 (41.2%) 0.873 
B cell depletion 
     Complete 10 4/10 (40.0%) 6/16 (37.5%) 0.831 
Concomitant Therapies 
     HCQ 11 2/9 (22%) 10/17 (58.8%) 0.075 
     IS 15 7/9 (78%) 11/17 (64.7%) 0.492 
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ACLE = Acute Cutaneous Lupus Erythematosus 
SCLE = Subacute Cutaneous Lupus Erythematosus 
CCLE = Chronic Cutaneous Lupus Erythematosus 
LENS = Lupus Erythematosus non-specific lesions 
dsDNA = anti-double stranded DNA antibodies 
Ro = anti-Ro/SSA antibodies 
La = anti-La/SSB antibodies 
RNP = anti-ribonuclear protein antibodies 
C3, C4 = complement components C3 and C4 
HCQ = hydroxychloroquine 
IS = conventional immunosuppressant 
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Table 2: Factors association with cutaneous flare after rituximab 
Characteristic Total (n=32) Flare (n=12) No Flare (n=18) p 
Subtype of skin disease at baseline 
     ACLE 14 6/12 (50.0%) 8/20 (40.0%) 
0.002 
     SCLE 2 0/12 (0.0%) 2/20 (100.0%) 
     CCLE 8 0/12 (0.0%) 8/20  (40.0%) 
     LENS 2 0/12 (0.0%) 2/20 (10.0%) 
     No skin disease 6 6/12 (100.0%) 0/20 (0.0%) 
Subtype of skin disease at flare 
     ACLE 0 0 N/A 
N/A 
     SCLE 4 4 N/A 
     CCLE 5 5 N/A 
     LENS/NONLE 3 3 N/A 
Serology at baseline 
     dsDNA 17 7/12 (58.3%) 11/20 (55.0%) 0.854 
     Ro 17 8/12 (66.7%) 11/20 (55.0%) 0.515 
     La 9 4/12 (33.3%) 5/20 (25.0%) 0.612 
     Sm 4 0/12 (0.0%) 4/20 (22.2%) 0.098 
     RNP 7 4/12 (33.3%) 4/20 (20.0%) 0.399 
     Low C3 12 6/12 (50.0%) 6/20 (30.0%) 0.258 
     Low C4 14 6/12 (50.0%) 8/20 (40.0%) 0.581 
B cell depletion 
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     Complete 12 
3/12 (25.0%) 
9/20 (45.0%) 0.258 
Concomitant Therapies 
     HCQ 12 4/12 (33.3%) 9/20 (45.0%) 0.515 
     IS 24 10/12 (83.3%) 14/20 (70.0%) 0.399 
ACLE = Acute Cutaneous Lupus Erythematosus 
SCLE = Subacute Cutaneous Lupus Erythematosus 
CCLE = Chronic Cutaneous Lupus Erythematosus 
LENS = Lupus Erythematosus non-specific lesions 
NONLE = skin disease not typically seen in patients with cutaneous or systemic 
lupus 
dsDNA = anti-double stranded DNA antibodies 
Ro = anti-Ro/SSA antibodies 
La = anti-La/SSB antibodies 
RNP = anti-ribonuclear protein antibodies 
C3, C4 = complement components C3 and C4 
HCQ = hydroxychloroquine 
IS = conventional immunosuppressant 
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Figure Legends 
Figure 1a: Comparative response in individual BILAG domains 
Response in the four most common domains rated BILAG A or B at baseline.  Bars 
show percentage of patients with scores A, B or C before (Pre) and 6 months after 
(Post) rituximab. 
 
Figure 1b:  BILAG response in non-cutaneous domains according to 
cutaneous response. 
Total numerical BILAG domain score in the four most common domains rated BILAG 
A or B at baseline for patients with cutaneous response (n=10) or cutaneous non-
response (n=16). 
 
List of Supplementary Data 
Supplement 1 
Table S1:   Details of responses in individual patients 
Table S2:  Details of histological studies 
 
Supplement 2 
Figure S1:  Photographs before and after rituximab in patient with SCLE and 
good response 
Figure S2: Histology from same patient as Figure S1 before rituximab 
Figure S3:  Photographs of active discoid LE in B cell depleted patient with good 
haematological response 
Figure S4:  Biopsy of active discoid lesion in B cell depleted patient with good 
neurological response 
Figure S5:  Biopsy demonstrating active pemphigus in B cell depleted patient 
with no prior cutaneous involvement of SLE 
Figure S6:  Photographs showing patient with persistent active disseminated 
discoid LE after 2 cycles of rituximab 
Figure S7: Biopsy with H&E and mucin staining from a patient who developed 
SCLE after rituximab 
Figure S8: DIF images demonstrating IgM and C3c deposition during B cell 
depletion 
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Figure 1a: Comparative response in individual BILAG domains: Response in the four most common domains 
rated BILAG A or B at baseline.  Bars show percentage of patients with scores A, B or C before (Pre) and 6 
months after (Post) rituximab.  
 
Figure 1b:  BILAG response in non-cutaneous domains according to cutaneous response.  
Total numerical BILAG domain score in the four most common domains rated BILAG A or B at baseline for 
patients with cutaneous response (n=10) or cutaneous non-response (n=16).  
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Supplement 1 
Table S1: Details of responses in individual patients 
 
Case 
Before Rituximab After Rituximab 
Mucocutaneous 
BILAG 
Overall 
Mucocutaneous 
Response Description Classification Description 
Flare 
Classification 
Pre Post 
1* Malar ACLE ACLE Persistent malar ACLE   B B Non Response 
2* Malar ACLE ACLE Resolved   B D Improved 
3* Malar ACLE ACLE Resolved   B D Improved 
4 Malar ACLE ACLE Resolved   B D Improved 
5 
Malar, chest and upper limb 
ACLE 
ACLE Resolved   B D 
Improved 
6 Malar ACLE ACLE Resolved   B D Improved 
7 Malar ACLE ACLE Resolved   B D Improved 
8 Malar ACLE ACLE - change   B B Non Response 
9* Widespread typical acute LE ACLE 
Transient improvement, developed 
disseminated discoid LE at 6 months 
CCLE B B 
Switch / Flare 
10* Mild malar ACLE ACLE 
Initial improvement, developed facial discoid 
LE at 10 months (Figure S4) 
CCLE B B 
Switch / Flare 
11* 
Widespread, strongly 
photoaggravated acute LE 
unresponsive to HCQ 
ACLE 
Developed disseminated discoid LE at 6 
months (usually uncommon in male -n-
smokers).  Became responsive to HCQ. 
CCLE B B 
Switch / Flare 
12* 
Acute facial LE with diffuse -n-
scarring alopecia 
ACLE 
Developed disseminated, scarring discoid LE 
with acral LE (a variant of CCLE) at 3-4 
months 
CCLE B B 
Switch / Flare 
13* Widespread ACLE ACLE 
Initial improvement, developed biopsy-proven 
SCLE with neutrophilia at 7 months 
SCLE B B 
Switch / Flare 
14 
ACLE with typical biopsy, 
positive IF (Figure S9). 
ACLE 
Developed psoriasiform lesions with interface 
dermatitis but negative IF (Figure S9) 
LENS B A 
Switch / Flare 
15 
Papulosquamous SCLE 
(Figures S1 and S2) 
SCLE Complete resolution (Figure S1)   A D 
Improved 
16* Papulosquamous SCLE SCLE Papulosquamous SCLE A A Non Response 
17* 
Numerous discoid lesions on 
face only 
CCLE 
Persistently active discoid LE during B cell 
depletion.  Discoid lesions resolved 3 years 
later when thrombocytopenia relapsed.  
(Figure S3) 
  B B 
Non Response 
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